Diasorin Molecular, LLC

Diasorin Molecular, LLC, a foreign-owned manufacturer of molecular diagnostic reagents, analyzers, and test kits headquartered in Cypress, California, operates as a prime contractor (100% of recent awards) supplying specialized infectious disease diagnostics to the Department of Veterans Affairs healthcare system and the Department of Defense's medical operations. The vendor competes on full-and-open basis with no set-aside designations across its federal footprint, competing on proprietary diagnostic technology and sole-source contract justifications rather than on protected categories.

Diasorin Molecular's federal capability portfolio centers on real-time polymerase chain reaction (PCR) analyzers, molecular diagnostic test kits, and reagent supplies for detecting COVID-19, herpes simplex virus (HSV), cytomegalovirus (CMV), and emerging pathogens including Candida auris. Representative recent work includes a $30.954 million definitive contract awarded by the Office of the Assistant Secretary for Preparedness and Response (September 2022) to develop and verify point-of-care molecular diagnostics platforms for pharmacy networks, a $997.2 million single-award Blanket Purchase Agreement with VA Veterans Integrated Service Network 1 (VISN 1, awarded May 2025, ultimate completion April 2030) for herpes and CMV testing reagents supporting New England VA medical centers, and a $300 thousand single-award Indefinite Delivery Contract with VA VISN 10 (December 2025, completion November 2030) for Liaison MDX Candida auris screening diagnostic systems. Across these vehicles, Diasorin has delivered Simplexa COVID-19 direct kits, Liaison MDX thermocyclers and consumables, and specialized screening reagents to support VA laboratory diagnostics and infection prevention across multiple regions.

Customer concentration is steep and heavily weighted toward VA healthcare networks. The top five funding entities account for 99% of combined potential value. VA VISN 23 (Southern California region) dominates by award count (27 awards, $20.6 million combined potential value), followed by VA VISN 1 (16 awards, $5.3 million), VA VISN 10 (Cincinnati-based, 10 awards, $2.1 million), the Defense Health Agency (7 awards, $1.2 million), and VA VISN 16 (5 awards, $54 thousand). The rankings reveal a dollars-versus-volume split: by potential value, the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response leads with three awards totaling $35.7 million (the single $30.954 million pharmacy network contract anchors that figure), but by count, VA VISN 23 dominates the active operational footprint. Diasorin holds five active Indefinite Delivery Contracts and Blanket Purchase Agreements across VA and Defense Health Agency, with the largest vehicles being an IDC with VA VISN 23 (17 task orders, $2 million combined potential value) and an IDC with VA VISN 1 (reflecting the single-award $997.2 million BPA restructured across multiple task-order records).

Diasorin Molecular's recent activity shows volatility: 13 awards in FY2022, declining to 4 in FY2023 and 2 in FY2024, then rebounding to 11 in FY2025 and 2 through May 2026. Eleven awards with combined potential value of $1.8 million face ultimate completion within the next twenty-four months and therefore present recompete exposure; the largest near-term recompete is the VA VISN 23 $10 million IDC reaching completion September 2026. Service Contract Inventory data covering federal service contracts above the $150,000 threshold shows minimal SCI activity: $6.1 million invoiced in FY2024 across 10.2 FTEs on one prime contract record, with no reportable service-contract invoicing in FY2022 or FY2023. The FY2024 SCI rate ran at a flat $286.39/hr (10th, median, and 90th percentiles all identical), suggesting a single large service-level contract or purchase order structure. SCI does not capture Diasorin's product sales (test kits, reagents, analyzers), which dominate the award portfolio by NAICS and PSC: 42 awards fall under Analytical Laboratory Instrument Manufacturing (NAICS 334516), 22 under In-Vitro Diagnostic Substance Manufacturing (NAICS 325413), and task orders cluster in Laboratory Equipment and Supplies (PSC 6050) and In Vitro Diagnostic Substances, Reagents, Test Kits and Sets (PSC 6550). Across all SCI-reportable prime contracts, Diasorin delivers 100% of work in-house with zero subcontractor hour share, reflecting its integrated manufacturing and supply model.

Diasorin Molecular is a subsidiary of Diasorin Inc., a foreign-owned parent corporation headquartered in Stillwater, Minnesota, with registered federal contract awardee status. The parent holds federal contract vehicles but does not appear as a prime awardee on current federal awards; all visible federal work flows through Diasorin Molecular LLC as the executing entity. The vendor's federal footprint is concentrated in FDA-cleared molecular diagnostic products and sole-source or limited-competition procurements tied to proprietary analyzer platforms (Liaison MDX systems) and reagent formulations, with performance spanning VA facilities in Connecticut, New England, Southern California, the Cincinnati region, and military medical centers at Joint Base Lewis-McChord, Washington. All awards carry firm fixed-price structures with no cost-reimbursable or time-and-materials components, and no awards are set aside for small business, minority-owned, women-owned, or other federal set-aside categories.